150 related articles for article (PubMed ID: 35129651)
1. The diagnostic accuracy and clinical impact of FDG-PET/CT follow-up for patients on adjuvant immunotherapy for high-risk malignant melanoma.
Andersen JAS; Spatzek AD; Vilstrup MH; Grupe P; Hess S; Holdgaard PC; Bastholt L; Gerke O; Hildebrandt MG
Eur J Nucl Med Mol Imaging; 2022 Jun; 49(7):2342-2351. PubMed ID: 35129651
[TBL] [Abstract][Full Text] [Related]
2. Clinical and Prognostic Value of
Albano D; Familiari D; Fornito MC; Scalisi S; Laudicella R; Galia M; Grassedonio E; Ruggeri A; Ganduscio G; Messina M; Spada M; Midiri M; Alongi P
Curr Radiopharm; 2020; 13(1):42-47. PubMed ID: 31595860
[TBL] [Abstract][Full Text] [Related]
3.
Jaeger ZJ; Williams GA; Chen L; Mhlanga JC; Cornelius LA; Fields RC
J Surg Oncol; 2022 Mar; 125(3):525-534. PubMed ID: 34741547
[TBL] [Abstract][Full Text] [Related]
4. The use of FDG-PET/CT to detect early recurrence after resection of high-risk stage III melanoma.
Stahlie EHA; van der Hiel B; Stokkel MPM; Schrage YM; van Houdt WJ; Wouters MW; van Akkooi ACJ
J Surg Oncol; 2020 Dec; 122(7):1328-1336. PubMed ID: 32783266
[TBL] [Abstract][Full Text] [Related]
5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
6. 18F-FDG PET/CT and Melanoma: Value of Fourth and Subsequent Posttherapy Follow-up Scans for Patient Management.
Mena E; Taghipour M; Sheikhbahaei S; Mirpour S; Xiao J; Subramaniam RM
Clin Nucl Med; 2016 Sep; 41(9):e403-9. PubMed ID: 27355846
[TBL] [Abstract][Full Text] [Related]
7.
Lawal I; Lengana T; Ololade K; Boshomane T; Reyneke F; Modiselle M; Vorster M; Sathekge M
Nuklearmedizin; 2017 Jun; 56(3):83-89. PubMed ID: 28154879
[TBL] [Abstract][Full Text] [Related]
8. Surveillance imaging with FDG-PET/CT in the post-operative follow-up of stage 3 melanoma.
Lewin J; Sayers L; Kee D; Walpole I; Sanelli A; Te Marvelde L; Herschtal A; Spillane J; Gyorki D; Speakman D; Estall V; Donahoe S; Pohl M; Pope K; Chua M; Sandhu S; McArthur GA; McCormack CJ; Henderson M; Hicks RJ; Shackleton M
Ann Oncol; 2018 Jul; 29(7):1569-1574. PubMed ID: 29659679
[TBL] [Abstract][Full Text] [Related]
9. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
[TBL] [Abstract][Full Text] [Related]
10. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
[TBL] [Abstract][Full Text] [Related]
11. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma.
Wagner JD; Schauwecker D; Davidson D; Logan T; Coleman JJ; Hutchins G; Love C; Wenck S; Daggy J
Cancer; 2005 Aug; 104(3):570-9. PubMed ID: 15977211
[TBL] [Abstract][Full Text] [Related]
12. S-100B as an extra selection tool for FDG PET/CT scanning in follow-up of AJCC stage III melanoma patients.
Deckers EA; Wevers KP; Muller Kobold AC; Damude S; Vrielink OM; van Ginkel RJ; Been LB; van Leeuwen BL; Hoekstra HJ; Kruijff S
J Surg Oncol; 2019 Nov; 120(6):1031-1037. PubMed ID: 31468535
[TBL] [Abstract][Full Text] [Related]
13. Association of Fludeoxyglucose F 18-Labeled Positron Emission Tomography and Computed Tomography With the Detection of Oropharyngeal Cancer Recurrence.
Sivarajah S; Isaac A; Cooper T; Zhang H; Puttagunta L; Abele J; Biron V; Harris J; Seikaly H; O' Connell DA
JAMA Otolaryngol Head Neck Surg; 2018 Nov; 144(11):1037-1043. PubMed ID: 30242338
[TBL] [Abstract][Full Text] [Related]
14. Role of
Dolci C; Ceppi L; Guerra L; Crivellaro C; Lamanna M; Adorni M; Elisei F; Bonazzi CM; Sina F; Fruscio R; Messa C
Int J Gynecol Cancer; 2019 Oct; 29(8):1298-1303. PubMed ID: 31366569
[TBL] [Abstract][Full Text] [Related]
15. Performance of Long-Term CT and PET/CT Surveillance for Detection of Distant Recurrence in Patients with Resected Stage IIIA-D Melanoma.
Turner RM; Dieng M; Khanna N; Nguyen M; Zeng J; Nijhuis AAG; Nieweg OE; Einstein AJ; Emmett L; Lord SJ; Menzies AM; Thompson JF; Saw RPM; Morton RL
Ann Surg Oncol; 2021 Aug; 28(8):4561-4569. PubMed ID: 33393039
[TBL] [Abstract][Full Text] [Related]
16. Can integrated 18F-FDG PET/MR replace sentinel lymph node resection in malignant melanoma?
Schaarschmidt BM; Grueneisen J; Stebner V; Klode J; Stoffels I; Umutlu L; Schadendorf D; Heusch P; Antoch G; Pöppel TD
Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2093-2102. PubMed ID: 29876618
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic value of integrated ¹⁸F-fluoro-2-deoxyglucose positron emission tomography/computed tomography in recurrent epithelial ovarian cancer: accuracy of patient selection for secondary cytoreduction in 134 patients.
Lee YJ; Kim YM; Jung PS; Lee JJ; Kim JK; Kim YT; Nam JH
J Gynecol Oncol; 2018 May; 29(3):e36. PubMed ID: 29400023
[TBL] [Abstract][Full Text] [Related]
18. Two decades of FDG-PET/CT in seminoma: exploring its role in diagnosis, surveillance and follow-up.
Conduit C; Koh TT; Hofman MS; Toner GC; Goad J; Lawrentschuk N; Tai KH; Lewin JH; Tran B
Cancer Imaging; 2022 Oct; 22(1):58. PubMed ID: 36209121
[TBL] [Abstract][Full Text] [Related]
19. Can Baseline [
Bianchi A; De Rimini ML; Sciuto R; Annovazzi A; Di Traglia S; Bauckneht M; Lanfranchi F; Morbelli S; Nappi AG; Ferrari C; Rubini G; Panareo S; Urso L; Bartolomei M; D'Arienzo D; Valente T; Rossetti V; Caroli P; Matteucci F; Aricò D; Bombaci M; Caponnetto D; Bertagna F; Albano D; Dondi F; Gusella S; Spimpolo A; Carriere C; Balma M; Buschiazzo A; Gallicchio R; Storto G; Ruffini L; Scarlattei M; Baldari G; Cervino AR; Cuppari L; Burei M; Trifirò G; Brugola E; Zanini CA; Alessi A; Fuoco V; Seregni E; Deandreis D; Liberini V; Moreci AM; Ialuna S; Pulizzi S; Evangelista L
Cancer Biother Radiopharm; 2023 May; 38(4):256-267. PubMed ID: 37098169
[No Abstract] [Full Text] [Related]
20. Initial [18F]FDG PET/CT in high-risk DTC patients. A three-year follow-up.
Ruhlmann M; Binse I; Bockisch A; Rosenbaum-Krumme SJ
Nuklearmedizin; 2016 Jun; 55(3):99-103. PubMed ID: 26830084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
